PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined its Board as Chair, and Stephen…
PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics
